#Sweden #Gothenburg #revenue growth #Zinzino #sales report

Zinzino's Remarkable November Sales Growth

In a recently released preliminary sales report, Zinzino AB (PUBL.) has reported an impressive revenue increase of 26% compared to the previous year for November 2024. The total revenue reached SEK 252.7 million, up from SEK 201.1 million the prior November, indicating a robust performance across its diverse sales markets.

This growth extension is not limited to Zinzino's own revenues. The external sales from Faun Pharma, a subsidiary, also saw a substantial increase of 33%, amounting to SEK 10.0 million. The collective revenues of the entire Zinzino Group soared to SEK 262.7 million for November, a remarkable rise from SEK 208.6 million in November 2023.

For the year-to-date period (January to November 2024), Zinzino reported accumulated revenues of SEK 1955.9 million, marking a 21% increase from SEK 1611.0 million in the same period of the previous year. This performance illustrates a consistent upward trend amid varying global market conditions.

Regional Revenue Breakdown

The financial performance of Zinzino was aided by impressive sales across different regions. Here’s a breakdown of the revenue across various geographical markets:

• - The Nordics: Reached SEK 29.0 million, a 4% increase from SEK 27.9 million in November 2023.
• - Central Europe: Showed remarkable growth of 42%, bringing in SEK 70.9 million compared to SEK 49.9 million a year prior.
• - East Europe: Experienced a modest increase of 5%, amounting to SEK 52.4 million.
• - South West Europe: Enjoyed solid growth of 27%, totaling SEK 45.1 million.
• - The Baltics: Increased by 25%, bringing their revenue to SEK 16.2 million.
• - North America: Demonstrated staggering growth of 70%, reaching SEK 25.9 million.
• - Asia-Pacific: Gained a healthy 30%, contributing SEK 10.8 million to the overall revenue.
• - Africa: Increased by 60%, bringing in SEK 2.4 million.

This diverse growth pattern indicates that Zinzino is not overly reliant on any single market, which allows for a more stable financial foundation. For instance, while the Nordics showed growth of just 4%, other areas like North America and Central Europe have become major contributors to overall revenue.

Future Outlook

As Zinzino continues to forge ahead, the positive trends emerging from their sales data suggest a strong future outlook. The company's strategic initiatives to expand into new markets and enhance product offerings appear to be paying off.

CEO Dag Bergheim Pettersen expressed confidence in sustaining this growth trajectory. He stated, "Our increases in both the Zinzino and Faun Pharma sectors affirm our commitment to innovation and customer satisfaction. We aim to maintain this momentum and explore new avenues for growth in the upcoming year."

Conclusion

The preliminary sales reports for Zinzino for November 2024 reflect a dynamic performance backed by increased global demand and successful market strategies. As businesses navigate the complexities of global commerce, Zinzino's results serve as a beacon of growth, signifying resilience and adaptability in an ever-evolving marketplace. Investors and stakeholders will be keenly watching how the company will leverage its momentum into 2025, as the first eleven months of the fiscal year have laid strong groundwork for future endeavors.